Risk factor
High price volatility
Profitability factor
Favourable analyst view
About
Hanall Biopharma Co., Ltd. is a pharmaceutical enterprise dedicated to the research, development, and global commercialization of its healthcare products. The company operates both within South Korea and across international markets, providing a diverse portfolio that includes specialized prescription medications and various over-the-counter (OTC) remedies. Their product line addresses an extensive range of medical conditions, encompassing: gastrointestinal disorders like ulcers, gastritis, constipation, bloating, and hemorrhoids; cardiovascular and cerebrovascular ailments such as hypertension, atherosclerosis, acute coronary syndrome, and thromboembolic events; metabolic and endocrine conditions including diabetes and hypothyroidism; and bone health issues such as osteoporosis, rickets, and osteomalacia. Additionally, Hanall Biopharma offers treatments for chronic kidney failure, various fungal infections (like candidiasis), and men's health concerns including erectile dysfunction, prostatic hyperplasia, and prostate cancer. Established in 1973, the company's central operations are based in Seoul, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Target Price
The average target price of 009420.KS is 87828 and suggests 77.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation t